iSonea wins CE Mark for AirSonea
09 September, 2013 by Dylan Bushell-EmblingiSonea (ASX:ISN) has gained the certification required for a CE Mark for its AirSonea wheeze monitoring tool, paving the way for an EU launch following its debuts in Australia and the US.
ACIP releases options paper on innovation patents
05 September, 2013The Advisory Council on Intellectual Property (ACIP) has just released an Options Paper for its Review of the Innovation Patent System. ACIP is seeking stakeholder comments on policy issues that address the full range of possibilities for the innovation patent system.
Alchemia narrows FY13 loss by $10.3m
03 September, 2013 by Dylan Bushell-EmblingRevenue from fonadaparinux sales and R&D Tax Incentive benefits helped Alchemia (ASX:ACL) reduce its FY13 loss by more than 68% to $4.8m.
AusBiotech responds to Qld review of its Gene Technology Act
03 September, 2013Amid 48 submissions, AusBiotech responded to the Queensland 'Review of the Gene Technology Act 2001 (Qld)', seeking support for a nationally consistent scheme for gene technology regulation.
Mesoblast bolsters cash position in FY13
30 August, 2013 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) recent $170m capital raising allowed the company to close out FY13 with total available funds of $315m.
Call for nominations to the board of directors of AusBiotech
29 August, 2013Further to the notice of the forthcoming election for the board of directors of AusBiotech for 2013-14, nominations are now open for eligible AusBiotech members.
Coalition promises funding for agriculture R&D
29 August, 2013The Coalition has formally released its agricultural policy, which promises to allocate $100 million to research and development in the sector.
Pharmaxis reimbursement talks delayed in France
29 August, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) will cut back on resources dedicated to a launch of CF treatment Bronchitol in France, due to delays reaching agreement with the CEPS on reimbursement.
Calzada narrows FY13 loss by 45%
28 August, 2013 by Dylan Bushell-EmblingA higher R&D tax benefit in FY13 helped Calzada (ASX:CZD) narrow its loss for the FY13 financial year to $1.5m.
FDA knocks back QRxPharma's MoxDuo again
28 August, 2013 by Dylan Bushell-EmblingQRxPharma (ASX:QRL) will need to resubmit its FDA application for MoxDuo IR again, after the regulator issued a second Complete Response Letter.
A win for the health industry in the Curtin Commercial Innovation Awards
27 August, 2013The 2013 Curtin Commercial Innovation Awards winners have been announced, with the three winning entries each having strong or potential applications in the medical industry.
Coalition pledges "new approach" to manufacturing
27 August, 2013AusBiotech has welcomed 'The Coalition’s Policy to Boost the Competitiveness of Australian Manufacturing' with its support for a "new approach" to manufacturing and a returned focus to Australian industry and SMEs.
Allied Healthcare gets CE Mark for CardioCel
26 August, 2013 by Dylan Bushell-EmblingAfter securing regulatory approval, Allied Healthcare (ASX:AHZ) now expects to start selling its CardioCel heart patch in Europe in calendar Q4.
Nexvet picks up a $1.5m CA grant
23 August, 2013 by Dylan Bushell-EmblingCommercialisation Australia will award Nexvet a further $1.5m in grant funding to help the company bring its PETisation technology to market.
AusBiotech welcomes new venture capital fund for biotech
22 August, 2013AusBiotech has commended the Labor government’s response to the Strategic Review of Health and Medical Research (The McKeon Review) and its pledge to establish the $250 million Medical Research Innovation Fund (MRIF).
